Duncan-Williams Maintains Buy on eResearch Technology (ERES)

Duncan-Williams is out with its report on eResearch Technology ERES, maintaining Buy. In a note to clients, Duncan-Williams writes, "ERT reported Q1:11 revenue and adjusted EPS of $41.7 million and $0.09, below our revenue estimate of $42.5 million and above our adjusted EPS estimate of $0.07. This represents approximately 91% revenue growth and 80% EPS growth compared to the same period last year. Our estimates assume a normalized tax rate of 29%, exclude charges to G&A associated with the CRS acquisition, and exclude charges to COGS due to amortization of intangibles from the CRS acquisition. We are maintaining a BUY rating and our twelve month price target of $8.50." Shares of ERES closed Monday at $6.79.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsDuncan-WilliamseResearch technologyHealth CareLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!